Literature DB >> 21424938

Acute intrahepatic cholestasis accompanied with Chlamydophila pneumoniae infection.

Megumi Toyoda-Akui1, Hiroaki Yokomori, Fumihiko Kaneko, Yuki Shimizu, Hajime Takeuchi, Kumiko Tahara, Hide Yoshida, Hirobumi Kondo, Tadashi Motoori, Makoto Ohbu, Masaya Oda, Toshifumi Hibi.   

Abstract

We report a case of Chlamydophila (C.) pneumoniae infection presenting with fever and rapid intrahepatic cholestasis. A 63-year-old man had a week-long history of intermittent high fever and rapidly progressive jaundice with atypical erythema. The results of liver function tests were recorded. The results of all serological tests were negative; the IgM, IgG, and IgA titers for C. pneumoniae had increased, which indicates a C. pneumoniae infection. The patient's fever and liver dysfunction improved upon administration of minocycline. Light microscopic findings showed the presence of enlarged liver cells with clear cytoplasm, a few mitotic figures, multinucleated cells, and bile cholestasis. The electron microscopic appearance of liver biopsy showed that bile canaliculi exhibited intrahepatic forms of cholestasis. From the results of light and electron microscopy, we inferred atypical intrahepatic cholestasis, probably resulting from the C. pneumoniae infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424938     DOI: 10.1007/s00795-010-0535-y

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  26 in total

Review 1.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

Authors:  S F Dowell; R W Peeling; J Boman; G M Carlone; B S Fields; J Guarner; M R Hammerschlag; L A Jackson; C C Kuo; M Maass; T O Messmer; D F Talkington; M L Tondella; S R Zaki
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

Review 2.  Leptospirosis: a zoonotic disease of global importance.

Authors:  Ajay R Bharti; Jarlath E Nally; Jessica N Ricaldi; Michael A Matthias; Monica M Diaz; Michael A Lovett; Paul N Levett; Robert H Gilman; Michael R Willig; Eduardo Gotuzzo; Joseph M Vinetz
Journal:  Lancet Infect Dis       Date:  2003-12       Impact factor: 25.071

Review 3.  Sepsis-induced cholestasis.

Authors:  Nisha Chand; Arun J Sanyal
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

Review 4.  Chlamydia pneumoniae (TWAR) infections in children.

Authors:  J T Grayston
Journal:  Pediatr Infect Dis J       Date:  1994-08       Impact factor: 2.129

5.  Evaluation of serological tests detecting Chlamydophila pneumoniae-specific immunoglobulin M antibody.

Authors:  Naoyuki Miyashita; Yasushi Obase; Minoru Fukuda; Hisashi Shoji; Keiji Mouri; Shinichi Yagi; Koichiro Yoshida; Kazunobu Ouchi; Mikio Oka
Journal:  Intern Med       Date:  2006-11-15       Impact factor: 1.271

6.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.

Authors:  P Saikku; M Leinonen; L Tenkanen; E Linnanmäki; M R Ekman; V Manninen; M Mänttäri; M H Frick; J K Huttunen
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

7.  Erythema nodosum--a manifestation of Chlamydia pneumoniae (strain TWAR) infection.

Authors:  M Erntell; K Ljunggren; T Gadd; K Persson
Journal:  Scand J Infect Dis       Date:  1989

8.  Liver morphology and function in visceral leishmaniasis (Kala-azar).

Authors:  I A el Hag; F A Hashim; I A el Toum; M Homeida; M el Kalifa; A M el Hassan
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

9.  An unusual manifestation of Chlamydia pneumoniae infection: meningitis, hepatitis, iritis and atypical erythema nodosum.

Authors:  B Sundelöf; H Gnarpe; J Gnarpe
Journal:  Scand J Infect Dis       Date:  1993

10.  Countrywide epidemics of Chlamydia pneumoniae, strain TWAR, in Scandinavia, 1981-1983.

Authors:  J T Grayston; C Mordhorst; A L Bruu; S Vene; S P Wang
Journal:  J Infect Dis       Date:  1989-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.